Edesa Biotech, Inc. EDSA
2.22 USD +0.20 (+9.90%)
At closeNov 11, 2026, 7:28 PM EST
2.19 -0.03 -1.32%
After hours · Nov 11, 7:28 PM ET
1.85 Day range 2.31
0.80 52-week range 18.28
- YTD
- +56.34%
- 1 year
- +21.98%
News
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 39.0% to $2.98 during Monday's regular session. The market value of their outstanding shares is at $20.6 million. Heron Therapeutics…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers MaxCyte (NASDAQ:MXCT) stock increased by 21.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $130.0 million. Vir Biotechnology (NASDAQ:VIR)…
benzinga.com Edesa Biotech Enters Collaboration And License Agreement With Kyorin Pharmaceutical For Paridiprubart In Japan; Deal Valued At $140M+ With Potential Milestone Payments Under the terms of the agreement, Kyorin will obtain an exclusive license to further develop and commercialize Edesa’s drug candidate, paridiprubart, in Japan, in Acute Respiratory Distress Syndrome…
globenewswire.com Edesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in Japan TORONTO and TOKYO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for…
globenewswire.com Edesa Biotech to Present at Guggenheim Healthcare Innovation Conference TORONTO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers XORTX Therapeutics (NASDAQ:XRTX) shares moved upwards by 19.3% to $1.14 during Tuesday's after-market session. The company's market cap stands at $1.8 million. Edesa Biotech (NASDAQ:EDSA)…
benzinga.com Edesa Biotech Receives FDA Clearance For Its Investigational New Drug Application For Its Phase 2 Clinical Trial Of EB06 In Vitiligo Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported that the U.S. Food and…
globenewswire.com Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study TORONTO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers SCWorx Corp. - Common Stock (NASDAQ:WORX) shares moved upwards by 48.8% to $6.25 during Thursday's after-market session. XORTX Therapeutics (NASDAQ:XRTX) stock increased by 22.7% to $2.27.…
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Elutia (NASDAQ:ELUT) stock moved upwards by 17.2% to $0.94 during Thursday's after-market session. The market value of their outstanding shares is at $34.9 million. Intelligent Bio Solutions…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular session. The market value of their outstanding shares is at $2.1 billion. SCYNEXIS (NASDAQ:SCYX) stock…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Autonomix Medical (NASDAQ:AMIX) stock moved upwards by 142.1% to $13.0 during Monday's after-market session. The company's market cap stands at $5.1 million. Picard Medical (AMEX:PMI) stock…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Circle8 Group (NASDAQ:CIRC) shares increased by 18.2% to $0.77 during Thursday's pre-market session. The company's market cap stands at $60.1 million. The company's, Q2 earnings came out…
benzinga.com Edesa Biotech Stock Sinks After Fresh Capital Raise Edesa Biotech Stock falls in premarket trading as investors weigh a $25 million offering, new warrants and potential dilution.
globenewswire.com Edesa Biotech Announces Pricing of $25.0 Million Public Offering TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers BioVie (NASDAQ:BIVI) stock increased by 15.7% to $1.55 during Wednesday's after-market session. The market value of their outstanding shares is at $7.2 million. The company's, Q4 earnings…
benzinga.com Edesa Biotech Commences Common Stock Offering; Terms Undisclosed Edesa Biotech, Inc. (NASDAQ:EDSA) (the "Company" or "Edesa"), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today…
globenewswire.com Edesa Biotech Announces Proposed Public Offering TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics…- benzinga.com Edesa Biotech Q3 EPS $(0.60) Misses $(0.58) Estimate Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.58) by 3.45 percent. This is a 140 percent decrease over losses of…
globenewswire.com Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory…
globenewswire.com Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com Edesa Biotech Announces Exploratory Data For Its Anti-TLR4 Monoclonal Antibody Paridiprubart In Patients With Acute Kidney Injury And Respiratory Distress; Analyses Demonstrate Mortality Reduction Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today reported favorable exploratory data for…
globenewswire.com Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury TORONTO, June 05, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
globenewswire.com Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference TORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com Edesa Biotech Q2 EPS $(0.49) Misses $(0.26) Estimate Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.26) by 88.46 percent. This is a 63.33 percent decrease over losses of…
globenewswire.com Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
globenewswire.com Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit Selection Follows Positive Phase 3 Results for Paridiprubart Demonstrating Statistically Significant Mortality Reductions in ARDS Patients Selection Follows Positive Phase 3 Results for Paridiprubart…
benzinga.com Edesa Biotech Reaffirms Enrollment Timeline Guidance For Phase 2 Clinical Study Of EB06 In Moderate-To-Severe Nonsegmental Vitiligo Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today provided an update on…
globenewswire.com Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Why Box Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket Box Inc (BOX) shares jump 6.2% in pre-market trading after beating earnings expectations with $305.88M in revenue and 49 cents per share earnings.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Axon Enterprise Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Reported Earlier: Edesa Biotech Reports Phase 3 Data Show Paridiprubart Cuts 28-Day Mortality To 24% From 33% Across 278 Patients; Targeting Sepsis, Acute Kidney Injury And Pneumonia With New Patent Filings Results in a population of 278 patients affirm statistically significant mortality reductions
benzinga.com Edesa Biotech Announces Additional Data From Phase 3 Study Of Paridiprubart Results in a population of 278 patients affirm statistically significant mortality reductionsBenefits observed across severity groups and in subjects with serious comorbiditiesCompany files…
globenewswire.com Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory…
gurufocus.com Market Today: AI Fears Rattle Stocks; CPI Cools, Rivian Pops Guru Stock PicksRobert Bruce has made the following transactions:Reduce in NEE by 1.49%Ray Dalio has made the following transactions:Reduce in CNX by 13.43%Sold